Broker tips: HSBC, Hikma, Pearson
3rd May 2023 16:16
(Sharecast News) - Berenberg upgraded HSBC to 'buy' from 'hold' on Wednesday, keeping the price target at 780p, as it said the bank's return on tangible equity of around 13% and attractive growth potential are undervalued.
Read moreRBC Capital lifts Hikma price target, reiterates 'outperform'
3rd May 2023 12:56
(Sharecast News) - RBC Capital Markets lifted its price target on Hikma Pharmaceuticals on Wednesday to 2,050p from 1,950p as it reiterated its 'outperform' rating.
Read moreHikma upgrades FY guidance, cautious on Sudan impact
28th Apr 2023 08:00
(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance after a stronger-than-expected start to the year for its generics business but expressed concern about the impact of the current conflict in Sudan on operations.
Read moreHikma appoints Riad Mishlawi as CEO
12th Apr 2023 07:18
(Sharecast News) - Hikma Pharmaceuticals said Riad Mishlawi, president of the group's injectables business, has been appointed chief executive Officer, effective from September 1.
Read moreBerenberg raises target price on Hikma Pharmaceuticals
27th Feb 2023 09:38
(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update.
Read moreCompetition in generics sees Hikma Pharmaceuticals's profits decline by a tenth
23rd Feb 2023 07:59
(Sharecast News) - Hikma Pharmaceuticals posted lower full-year profits as stiff competition in generics saw its top line growth flatten out.
Read moreDirector dealings: Hikma Pharmaceuticals director snaps up shares
18th Jan 2023 15:07
(Sharecast News) - Hikma Pharmaceuticals revealed on Wednesday that non-executive director Deneen Vojta had acquired 1,000 ordinary shares in the FTSE 250-listed drugmaker.
Read moreHikma launches generic narcolepsy solution in US
3rd Jan 2023 07:46
(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.
Read moreRBC Capital Markets starts Hikma at 'outperform'
6th Dec 2022 10:48
(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.
Read moreCredit Suisse initiates coverage of Hikma at 'outperform'
15th Nov 2022 12:10
(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.
Read moreHikma reiterates FY guidance amid 'strong momentum'
3rd Nov 2022 08:39
(Sharecast News) - Drugmaker Hikma Pharmaceuticals reiterated full-year guidance on Thursday, citing "strong momentum" in its injectables and branded units, but also cautioned that had begun to see the effects of the global inflationary environment on costs.
Read moreBerenberg initiates coverage on Hikma Pharmaceuticals at 'hold'
4th Oct 2022 08:46
(Sharecast News) - Analysts at Berenberg initiated coverage on drugmaker Hikma Pharmaceuticals at 'hold' on Tuesday, stating it was "waiting for the tide to turn".
Read moreBarclays downgrades Hikma to 'equalweight' on Generics concerns
5th Aug 2022 09:43
(Sharecast News) - Barclays downgraded Hikma Pharmaceuticals on Friday to 'equalweight' from 'overweight' and cut the price target to 1,750p from 2,250p as it said a lack of visibility in the generics division was a real concern.
Read moreHikma revenue flat, profits tumble in first half
4th Aug 2022 10:15
(Sharecast News) - Hikma shares were tumbling on Thursday morning after the pharmaceuticals company reported flat group revenue in its first half, at $1.21bn, as it slashed its guidance on its lagging generics business.
Read moreHikma's Siggi Olafsson stands down as CEO
24th May 2022 07:09
(Sharecast News) - Drugmaker Hikma Pharmaceuticals revealed on Tuesday that chief executive Siggi Olafsson has resigned from both the role and the company's board of directors in order to pursue other opportunities.
Read more